Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancer

Publication date: Available online 12 April 2017
Source:Human Pathology
Author(s): Baoquan Liu, Fei Su, Mingwei Chen, Yue Li, Xiuying Qi, Jianbing Xiao, Xuemei Li, Xiangchen Liu, Wenlong Liang, Yafang Zhang, Jianguo Zhang
The predictive value of serum miRNAs (ser-miRNA) for the response to neoadjuvant chemotherapy (NCT) and the prognosis of breast cancer patients was investigated in the current study. The study included 118 stage II/III breast cancer patients and 30 healthy adult women. Peripheral blood was drawn from participants before the start (baseline, BL), at the end of the second cycle (first evaluation during NCT, FEN), and at the end of NCT (second evaluation during NCT, SEN). The expression of ser-miRNAs was examined by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and their association with chemotherapy response and prognosis was analyzed. MiR-19a, miR-21, miR-125b, miR-155, miR-205, and miR-373 were significantly upregulated in the serum of breast cancer patients at BL, miR-451 was significantly downregulated, and miR-122 were unchanged compared with the levels in healthy women. The expression of ser-miR-125b and the changes of ser-miR-21 expression during NCT were associated with chemotherapy response and disease-free survival (DFS). In chemotherapy responders, ser-miR-125b expression was lower than that of non-responders at BL, FEN, and SEN, and ser-miR-21 levels decreased from BL to FEN and from BL to SEN. Survival analysis showed that patients with lower ser-miR-125b expression at BL, FEN, and SEN had favorable DFS, and those with decreased ser-miR-21 expression from BL to FEN and from BL to SEN had better DFS. In conclusion, ser-miR-21 and ser-miR-125b were identified as novel, noninvasive predictive markers for NCT response and prognosis in breast cancer.



http://ift.tt/2px7k7u